Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2014

Collaborative Arrangements

Collaborator revenues

During the three months ended March 31, 2014 and 2013, the Company recognized the following revenues attributable to the Janssen collaboration:

	Three Months Ended March 31,
	2014		2013
	(in thousands)
Royalty revenues (INCIVO)	$	4,935	$	39,044
Collaborative revenues:
Up-front and amendment payments revenues	$	—	$	3,107
Net reimbursement (payment) for telaprevir development costs	1,389		(27		)
Reimbursement for manufacturing services	—		10,299
Total collaborative revenues attributable to the Janssen collaboration	$	1,389	$	13,379
Total revenues attributable to the Janssen collaboration	$	6,324	$	52,423

During the three months ended March 31, 2014 and 2013, the Company recognized the following revenues attributable to the CFFT collaboration:

	Three Months Ended March 31,
	2014		2013
	(in thousands)
Collaborative revenues attributable to the CFFT collaboration	$	2,868	$	3,559

Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios)

A summary of net loss attributable to noncontrolling interest (Alios) for the three months ended March 31, 2013 is as follows:

	Three Months Ended March 31, 2013
	(in thousands)
Loss before benefit from income taxes	$	5,297
Decrease in fair value of contingent milestone and royalty payments	2,740
Benefit from income taxes	(3,426		)
Net loss attributable to noncontrolling interest (Alios)	$	4,611